Vaccines and Disease-Modifying Antirheumatic Drugs Practical Implications for the Rheumatologist

被引:45
|
作者
Friedman, Marcia A. [1 ]
Winthrop, Kevin L. [2 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Rheumatol, Mail Code OP09,3181 Southwest Sam Jackson Pk Rd, Portland, OR 97239 USA
[2] Oregon Hlth & Sci Univ, Dept Infect Dis, 840 SW Gaines Rd, Portland, OR 97239 USA
关键词
Vaccine; Rheumatoid arthritis; DMARD; Biologic; Anti-TNF; Rituximab; Immunogenicity; Efficacy; NECROSIS-FACTOR-ALPHA; B-VIRUS REACTIVATION; PNEUMOCOCCAL POLYSACCHARIDE VACCINATION; ADVISORY-COMMITTEE; ANTIBODY-RESPONSE; HERPES-ZOSTER; IMMUNIZATION PRACTICES; IMMUNE-RESPONSE; ARTHRITIS PATIENTS; INFLUENZA VACCINE;
D O I
10.1016/j.rdc.2016.09.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with rheumatoid arthritis are highly vulnerable to infections because of abnormalities in their immune system, and because of immunosuppressive effects of their medications. Vaccinations in this population are complicated by disease-modifying antirheumatic drugs, which also modulate or suppress the immune system and potentially decrease the immunogenicity and efficacy of the vaccines. We review the available data regarding the impact of rheumatoid arthritis therapy on the immunogenicity of various common vaccines. We also review rheumatoid arthritis specific vaccination recommendations, live vaccine safety concerns, and current gaps in our understanding of these issues."
引用
收藏
页码:1 / +
页数:14
相关论文
共 50 条
  • [21] Disease-modifying antirheumatic drugs: enhancing efficacy by combination
    Schnabel, A
    LANCET, 2004, 363 (9410): : 670 - 671
  • [22] Proposal for a new nomenclature of disease-modifying antirheumatic drugs
    Smolen, Josef S.
    van der Heijde, Desiree
    Machold, Klaus P.
    Aletaha, Daniel
    Landewe, Robert
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 3 - 5
  • [23] Safety overview of new disease-modifying antirheumatic drugs
    Cush, JJ
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2004, 30 (02) : 237 - +
  • [24] The unsustainable bubble of disease-modifying antirheumatic drugs in rheumatology
    Landewe, Robert B. M.
    LANCET RHEUMATOLOGY, 2021, 3 (04): : 306 - 312
  • [25] Immunizations in Adults Taking Disease-Modifying Antirheumatic Drugs
    Thome, Joel
    US PHARMACIST, 2013, 38 (04) : 38 - 43
  • [26] Survival of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Rosales Rosado, Zulema
    Leon, Leticia
    Freites Nunez, Dalifer
    Font Urgelles, Judit
    Leon Cardenas, Cynthia Milagros
    Vadillo Font, Cristina
    Rodriguez Rodriguez, Luis
    Jover Jover, Juan A.
    Abasolo Alcazar, Lydia
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [27] ADHERENCE TO DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATIC DISEASES
    Pineda Sic, Rita Angelica
    de Jesus Hernandez-Galarza, Ivan
    Castro-Gonzalez, Marielva
    Angel Galarza-Delgado, Dionicio
    Angel Villarreal-Alarcon, Miguel
    Allan Uriarte Botello, Rodolfo
    Ilizaliturri Guerra, Octavio
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1681 - 1681
  • [28] Psoriatic Disease: Update on Traditional Disease-modifying Antirheumatic Drugs
    Marchesoni, Antonio
    Lubrano, Ennio
    Cauli, Alberto
    Ricci, Massimo
    Manara, Maria
    JOURNAL OF RHEUMATOLOGY, 2015, 42 : 61 - 64
  • [29] A Clinical and Economic Review of Disease-Modifying Antirheumatic Drugs
    Sherine E. Gabriel
    Douglas Coyle
    Larry W. Moreland
    PharmacoEconomics, 2001, 19 : 715 - 728
  • [30] Disease-modifying drugs and vaccines for Alzheimer's disease
    Cummings, J.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S40 - S40